

Radiation Oncology Committee

Leadership

Chair.....Chul Ha, MD
 Vice-Chair Lisa Kachnic, MD
 Executive Officer..... Lisa Kachnic, MD
 Statistician..... Danika Lew, MA

Designates

Breast Committee liaison Reshma Jagsi, MD, DPhil
 Cancer Care Delivery Committee liaison Eileen Connolly, MD
 Cancer Control & Prevention Committee liaison Eileen Connolly, MD
 CNS Working Group liaison Tony Wang, MD
 Genitourinary Committee liaison James Yu, MD
 Gastrointestinal Committee liaison David Horowitz, MD
 Lung Committee liaison Henry Park, MD
 Lymphoma Committee liaison..... Sandy Constine, MD
 Melanoma Committee liaison..... Evan Wuthrick, MD

Time/Location

Friday, October 13, 2023 3:00 pm-5:00 pm
 Room: Comiskey (Concourse Level, West Tower)

Agenda

3:00 - 3:05 pm Welcome Chul S. Ha, MD
 3:05 - 3:10 pm Report from Executive Officer Lisa Kachnic, MD
 3:10 - 3:55 pm Keynote Lecture: New Paradigms for Image Based
 Response Assessment: Lawrence Schwartz, MD
 3:55 - 4:45 pm Reports by Committees

Breast

Report by liaison: Reshma Jagsi, MD, DPhil

S1706: A phase II randomized trial of olaparib administered concurrently with RT vs RT alone for inflammatory breast cancer. Reshma Jagsi, MD, DPhil

Randomized phase III trial of multimodality therapy in each subtype of stage IV oligometastatic breast cancer vs palliative therapy (under development). Shane Stecklein, MD, PhD

Re-radiation trial for in-breast recurrence (under development). Eileen Connolly, MD

CDK 4/6 inhibition concurrent with RT for ER+ locally advanced breast cancer (under development). Corey Speers, MD, PhD

CNS

Report by liaison: Tony Wang, MD

Phase II study of atezolizumab and tocilizumab with radiotherapy in patients with newly diagnosed MGMT unmethylated glioblastoma (under development). Tony Wang, MD

Gastrointestinal

Report by liaison: David Horowitz, MD

Phase II anal cancer protocol under development. David Horowitz, MD

Genitourinary

Report by liaison: James Yu, MD

Lung

Report by liaison: Henry Park, MD

S1914: A randomized phase III trial of induction/consolidation Atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC. Megan Daly, MD

S1933: A pilot study of hypofractionated radiotherapy followed by atezolizumab consolidation in stage II or III NSCLC patients with borderline performance status. Raid Aljumaily, MD

S1827: MRI brain surveillance alone versus MRI surveillance and prophylactic cranial irradiation: a randomized phase III trial in small-cell lung cancer. Chad Rusthoven, MD

NRG CC009: Phase III trial of SRS versus hippocampal-avoidant whole brain radiotherapy for 10 or fewer brain metastases from small cell lung cancer. Chad Rusthoven, MD

Sequencing of immunotherapy and chemotherapy in unresectable stage III non-small cell lung cancer. Henry D. Park, MD, MPH

Lymphoma

Report by liaison: Sandy Constine, MD

Melanoma

Report by liaison: Evan Wuthrick, MD

Secondary analysis for S1404. Evan Wuthrick, MD

Sarcoma

S2310: Phase II Randomized Study Testing Non-Inferiority of Shorter-Course Radiation Versus Standard Fractionation for High-Risk, Resectable Sarcoma. Jeremy Harris, MD

Radiation Oncology Committee

Cancer Control & Prevention Committee/ Cancer Care Delivery Committee

Report by liaison: Eileen Connolly, MD

S2304: A phase II randomized trial of intraoperative radiotherapy (IORT) vs. no IORT for postmenopausal women with low-risk ductal carcinoma in situ after breast conserving therapy (under development). Eileen Connolly, MD

4:35-4:40 pm Announcements

Search for liaisons for Cancer Survivorship Committee, Symptom Control & Quality of Life Committee, Immunotherapeutics Committee, and Early Therapeutics & Rare Cancer Committee.

Time for monthly calls

4:40-4:55 pm Open Forum

4:55-5:00 pm Closing remarks Chul S. Ha, MD